https://techcrunch.com/2021/10/20/uk-startup-healx-to-begin-clinical-trial-on-repositioned-drug-for-fragile-x-syndrome/

There are currently no approved cures for Fragile X syndrome – the most common cause of inherited intellectual disability. At the moment, the treatments are designed to manage symptoms, from anxiety to OCD or in rare cases, seizures. But a new clinical trial is soon to be underway at a UK startup. 

On Wednesday, drug discovery startup Healx announced that it has gained FDA investigational new drug status for a Phase 2a clinical trial on a repositioned drug (more on this later) for Fragile X syndrome. The study, which will evaluate the effects of a non-steroidal anti-inflammatory drug on Fragile X, will begin by January 2022, per the clinicaltrials.gov registration.